Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.11 EUR
Change Today +0.141 / 2.84%
Volume 204.2K
MDXH On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
Stuttgart
As of 11:35 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

mdxhealth (MDXH) Snapshot

Open
€5.20
Previous Close
€4.97
Day High
€5.22
Day Low
€5.10
52 Week High
02/24/15 - €5.88
52 Week Low
07/17/14 - €3.07
Market Cap
192.5M
Average Volume 10 Days
208.5K
EPS TTM
€-0.30
Shares Outstanding
37.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MDXHEALTH (MDXH)

Related News

No related news articles were found.

mdxhealth (MDXH) Related Businessweek News

No Related Businessweek News Found

mdxhealth (MDXH) Details

MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic assays and services for cancer assessment, and the personalized treatment of patients. It offers clinical molecular diagnostics solutions that provide physicians with tests for the identification and treatment of their cancer patients; and pharmaco molecular diagnostics solutions for the development of companion diagnostics, biomarker discovery, and clinical trial testing. The company’s product pipeline consists of ConfirmMDx that serve as an aid for physicians to assess DNA methylation status associated with presence or absence of cancer; and InformMDx, which provide prognostic assessment to distinguish between aggressive and non-aggressive tumors. Its products also comprise PredictMDx that offer predictive information to indicate drugs or treatment regimens that are to be most effective for the individual patient; and ClinicalMDx assays that are designed to aid in the assessment of the presence or absence of cancer, or provide indications of cancer recurrence or aggressiveness in the areas of prostate, colorectal, and lung cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA on October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.

84 Employees
Last Reported Date: 04/30/14
Founded in 2003

mdxhealth (MDXH) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €470.7K
Compensation as of Fiscal Year 2013.

mdxhealth (MDXH) Key Developments

MDxHealth SA Presents at BioCapital Europe 2015, Mar-26-2015 02:20 PM

MDxHealth SA Presents at BioCapital Europe 2015, Mar-26-2015 02:20 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.

MDxHealth SA Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 12:50 PM

MDxHealth SA Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 12:50 PM. Venue: The University Club, 1 W 54th St, New York, NY 10019, United States.

MDxHealth SA Announces Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015

MDxHealth SA announced audited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of €3,372,000 compared to €1,576,000 a year ago. LBITDA was €3,611,000 compared to €4,234,000 a year ago. Operating loss (LBIT) was €3,705,000 compared to €4,299,000 a year ago. Net loss was €3,019,000 compared to €4,387,000 a year ago. Basic earnings per share, basic were €0.08 against €0.13 a year ago. The increase revenues compared to the prior period was due to increased sales of ConfirmMDx and royalty and milestone payments from Exact Sciences. For the year, the company reported total revenues of €11,671,000 compared to €7,554,000 a year ago. LBITDA was €15,009,000 compared to €15,653,000 a year ago. Operating loss (LBIT) was €15,342,000 compared to €16,071,000 a year ago. Net loss was €15,256,000 compared to €16,175,000 a year ago. Basic earnings per share, basic were €0.40 against €0.47 a year ago. This loss is attributed to the continued investment in commercialization efforts in the U.S. and the delay in recognizing revenues from ConfirmMDx sales. For the fiscal year 2015, the company’s revenue expected to be between $16 million to $20 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDXH:BB €5.11 EUR +0.141

MDXH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $35.10 USD -0.07
Health Discovery Corp $0.02 USD +0.0018
Imperial Innovations Group PLC 475.00 GBp -10.00
Miraculins Inc C$0.10 CAD -0.01
Vermillion Inc $1.84 USD -0.01
View Industry Companies
 

Industry Analysis

MDXH

Industry Average

Valuation MDXH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.1x
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MDXHEALTH, please visit www.mdxhealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.